EGFR and lung cancer: Comprehensive next-generation sequencing should be performed on Stage Ib to IIIa lung cancer tumor tissue from non-smokers because actionable genomic alterations such as EGFR variants or ALK gene rearrangements are treated with targeted therapy such as the tyrosine kinase inhibitors osimertinib or lorlatinib, respectively.